Current insights into LMNA cardiomyopathies: Existing models and missing LINCs

References

• Lin F, Worman HJ. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem 1993; 268:16321-6; PMID:8344919
   PubMed Web of Science ®Google Scholar
• Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Science 2001; 114:4557-65; PMID:11792820
   PubMed Web of Science ®Google Scholar
• Crisp M, Liu Q, Roux K, Rattner JB, Shanahan C, Burke B, Stahl PD, Hodzic D. Coupling of the nucleus and cytoplasm: role of the LINC complex. J Cell Biol 2006; 172:41-53; PMID:16380439; http://dx.doi.org/10.1083/jcb.200509124
   PubMed Web of Science ®Google Scholar
• Mejat A, Misteli T. LINC complexes in health and disease. Nucleus 2010; 1:40-52; PMID:21327104; http://dx.doi.org/10.4161/nucl.1.1.10530
   PubMed Web of Science ®Google Scholar
• Jaalouk DE, Lammerding J. Mechanotransduction gone awry. Nat Rev Mol Cell Biol 2009; 10:63-73; PMID:19197333; http://dx.doi.org/10.1038/nrm2597
   PubMed Web of Science ®Google Scholar
• Wilson KL, Foisner R. Lamin-binding Proteins. Cold Spring Harb Perspect Biol 2010; 2:a000554; PMID:20452940; http://dx.doi.org/10.1101/cshperspect.a000554
   PubMed Web of Science ®Google Scholar
• Taylor MR, Fain PR, Sinagra G, Robinson ML, Robertson AD, Carniel E, Di Lenarda A, Bohlmeyer TJ, Ferguson DA, Brodsky GL, et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 2003; 41:771-80; PMID:12628721; http://dx.doi.org/10.1016/S0735-1097(02)02954-6
   PubMed Web of Science ®Google Scholar
• Bonne G, Leturcq F, Ben Yaou R. Emery-Dreifuss Muscular Dystrophy. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, et al., eds. GeneReviews(R). Seattle (WA), 1993
   Google Scholar
• Zhang L, Shen H, Zhao Z, Bing Q, Hu J. Cardiac effects of the c.1583 C–>G LMNA mutation in two families with Emery-Dreifuss muscular dystrophy. Mol Med Rep 2015; 12:5065-71; PMID:26165385
   PubMed Web of Science ®Google Scholar
• Chang SH, Tsai CT, Lai LP, Lei MH. Identification of a lamin A/C gene mutation in a Taiwanese family with limb girdle muscular dystrophy and cardiomyopathy. Inter J Cardiol 2010; 145:598-9; PMID:20615561; http://dx.doi.org/10.1016/j.ijcard.2010.06.014
   PubMed Web of Science ®Google Scholar
• Alastalo TP, West G, Li SP, Keinanen A, Helenius M, Tyni T, Lapatto R, Turanlahti M, Heikkila P, Kaariainen H, et al. LMNA Mutation c.917T>G (p.L306R) Leads to Deleterious Hyper-Assembly of Lamin A/C and Associates with Severe Right Ventricular Cardiomyopathy and Premature Aging. Hum Mutat 2015; 36:694-703; PMID:25820511; http://dx.doi.org/10.1002/humu.22793
   PubMed Web of Science ®Google Scholar
• Guo X, Ling C, Liu Y, Zhang X, Zhang S. A Case of Novel Lamin A/C Mutation Manifesting as Atypical Progeroid Syndrome and Cardiomyopathy. Can J Cardiol 2016; 32:1166 e29–31
   PubMed Web of Science ®Google Scholar
• Andre P, Schneebeli S, Vigouroux C, Lascols O, Schaaf M, Chevalier P. Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A. Am Heart J 2015; 169:587-93; PMID:25819867; http://dx.doi.org/10.1016/j.ahj.2014.12.021
   PubMed Web of Science ®Google Scholar
• Araújo-Vilar D, Lado-Abeal J, Palos-Paz F, Lattanzi G, Bandín Ma, Bellido D, Domínguez-Gerpe L, Calvo C, Pérez O, Ramazanova A, et al. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy. Clin Endocrinol 2008; 69:61-8; PMID:18031308; http://dx.doi.org/10.1111/j.1365-2265.2007.03146.x
   PubMed Web of Science ®Google Scholar
• Duparc A, Cintas P, Somody E, Bieth E, Richard P, Maury P, Delay M. A cardio-neurological form of laminopathy: dilated cardiomyopathy with permanent partial atrial standstill and axonal neuropathy. Pacing Clin Electrophysiol 2009; 32:410-5; PMID:19272076; http://dx.doi.org/10.1111/j.1540-8159.2008.02254.x
   PubMed Web of Science ®Google Scholar
• Galant D, Gaborit B, Desgrouas C, Abdesselam I, Bernard M, Levy N, Merono F, Coirault C, Roll P, Lagarde A, et al. A Heterozygous ZMPSTE24 Mutation Associated with Severe Metabolic Syndrome, Ectopic Fat Accumulation, and Dilated Cardiomyopathy. Cells 2016; 5; PMID:27120622; http://dx.doi.org/10.3390/cells5020021
   PubMedGoogle Scholar
• Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, American Heart A, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113:1807-16; PMID:16567565; http://dx.doi.org/10.1161/CIRCULATIONAHA.106.174287
   PubMed Web of Science ®Google Scholar
• Yajima T. Viral myocarditis: potential defense mechanisms within the cardiomyocyte against virus infection. Future Microbiol 2011; 6:551-66; PMID:21585262; http://dx.doi.org/10.2217/fmb.11.40
   PubMed Web of Science ®Google Scholar
• Yajima T, Knowlton KU. Viral myocarditis: from the perspective of the virus. Circulation 2009; 119:2615-24; PMID:19451363; http://dx.doi.org/10.1161/CIRCULATIONAHA.108.766022
   PubMed Web of Science ®Google Scholar
• Walker RK, Cousins VM, Umoh NA, Jeffress MA, Taghipour D, Al-Rubaiee M, Haddad GE. The good, the bad, and the ugly with alcohol use and abuse on the heart. Alcohol Clin Exp Res 2013; 37:1253-60; PMID:23527963; http://dx.doi.org/10.1111/acer.12109
   PubMed Web of Science ®Google Scholar
• Raj S, Franco VI, Lipshultz SE. Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment. Curr Treat Options Cardiovasc Med 2014; 16:315; PMID:24748018; http://dx.doi.org/10.1007/s11936-014-0315-4
   PubMedGoogle Scholar
• Yoshikawa T, Baba A, Nagatomo Y. Autoimmune mechanisms underlying dilated cardiomyopathy. Circ J 2009; 73:602-7; PMID:19246813; http://dx.doi.org/10.1253/circj.CJ-08-1151
   PubMed Web of Science ®Google Scholar
• Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Eng J Med 2011; 364:1643-56; PMID:21524215; http://dx.doi.org/10.1056/NEJMra0902923
   PubMed Web of Science ®Google Scholar
• Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93:841-2
   PubMed Web of Science ®Google Scholar
• Mestroni L, Rocco C, Gregori D, Sinagra G, Di Lenarda A, Miocic S, Vatta M, Pinamonti B, Muntoni F, Caforio AL, et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol 1999; 34:181-90; http://dx.doi.org/10.1016/S0735-1097(99)00172-2
   PubMed Web of Science ®Google Scholar
• Vatta M, Mohapatra B, Jimenez S, Sanchez X, Faulkner G, Perles Z, Sinagra G, Lin JH, Vu TM, Zhou Q, et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol 2003; 42:2014-27; PMID:14662268; http://dx.doi.org/10.1016/j.jacc.2003.10.021
   PubMed Web of Science ®Google Scholar
• Tsubata S, Bowles KR, Vatta M, Zintz C, Titus J, Muhonen L, Bowles NE, Towbin JA. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 2000; 106:655-62; PMID:10974018; http://dx.doi.org/10.1172/JCI9224
   PubMed Web of Science ®Google Scholar
• Franz WM, Cremer M, Herrmann R, Grunig E, Fogel W, Scheffold T, Goebel HH, Kircheisen R, Kubler W, Voit T, et al. X-linked dilated cardiomyopathy. Novel mutation of the dystrophin gene. Ann N Y Acad Sci 1995; 752:470-91; PMID:7755293; http://dx.doi.org/10.1111/j.1749-6632.1995.tb17457.x
   PubMed Web of Science ®Google Scholar
• Taylor MR, Slavov D, Ku L, Di Lenarda A, Sinagra G, Carniel E, Haubold K, Boucek MM, Ferguson D, Graw SL, et al. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation 2007; 115:1244-51; PMID:17325244; http://dx.doi.org/10.1161/CIRCULATIONAHA.106.644013
   PubMed Web of Science ®Google Scholar
• Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, Fan GC, Tsiapras D, Parekh RR, Dorn GW, 2nd, et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci U S A 2006; 103:1388-93; PMID:16432188; http://dx.doi.org/10.1073/pnas.0510519103
   PubMed Web of Science ®Google Scholar
• Parks SB, Kushner JD, Nauman D, Burgess D, Ludwigsen S, Peterson A, Li D, Jakobs P, Litt M, Porter CB, et al. Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am Heart J 2008; 156:161-9; PMID:18585512; http://dx.doi.org/10.1016/j.ahj.2008.01.026
   PubMed Web of Science ®Google Scholar
• Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, Mannarino S, Gambarin F, Favalli V, Grasso M, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 2008; 52:1250-60; PMID:18926329; http://dx.doi.org/10.1016/j.jacc.2008.06.044
   PubMed Web of Science ®Google Scholar
• Tesson F, Saj M, Uvaize MM, Nicolas H, Ploski R, Bilinska Z. Lamin A/C mutations in dilated cardiomyopathy. Cardiol J 2014; 21:331-42; PMID:24846508; http://dx.doi.org/10.5603/CJ.a2014.0037
   PubMed Web of Science ®Google Scholar
• van Weerd JH, Christoffels VM. The formation and function of the cardiac conduction system. Development 2016; 143:197-210; PMID:26786210; http://dx.doi.org/10.1242/dev.124883
   PubMed Web of Science ®Google Scholar
• Peters NS. Gap junctions and clinical cardiology: from molecular biology to molecular medicine. Eur Heart J 1997; 18:1697-702; PMID:9402442; http://dx.doi.org/10.1093/oxfordjournals.eurheartj.a015162
   PubMed Web of Science ®Google Scholar
• van Berlo JH, de Voogt WG, van der Kooi AJ, van Tintelen JP, Bonne G, Yaou RB, Duboc D, Rossenbacker T, Heidbuchel H, de Visser M, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med 2005; 83:79-83; PMID:15551023; http://dx.doi.org/10.1007/s00109-004-0589-1
   PubMed Web of Science ®Google Scholar
• Brodt C, Siegfried JD, Hofmeyer M, Martel J, Rampersaud E, Li D, Morales A, Hershberger RE. Temporal relationship of conduction system disease and ventricular dysfunction in LMNA cardiomyopathy. J Card Fail 2013; 19:233-9; PMID:23582089; http://dx.doi.org/10.1016/j.cardfail.2013.03.001
   PubMed Web of Science ®Google Scholar
• Maron BJ, Thompson PD, Puffer JC, McGrew CA, Strong WB, Douglas PS, Clark LT, Mitten MJ, Crawford MH, Atkins DL, et al. Cardiovascular preparticipation screening of competitive athletes. A statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young), American Heart Association. Circulation 1996; 94:850-6; PMID:8772711; http://dx.doi.org/10.1161/01.CIR.94.4.850
   PubMed Web of Science ®Google Scholar
• Bonne G, Carrier L, Richard P, Hainque B, Schwartz K. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res 1998; 83:580-93; PMID:9742053; http://dx.doi.org/10.1161/01.RES.83.6.580
   PubMed Web of Science ®Google Scholar
• Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000; 355:58-60; PMID:10615904; http://dx.doi.org/10.1016/S0140-6736(99)06187-5
   PubMed Web of Science ®Google Scholar
• Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003; 107:2227-32; PMID:12707239; http://dx.doi.org/10.1161/01.CIR.0000066323.15244.54
   PubMed Web of Science ®Google Scholar
• Marston S, Copeland O, Jacques A, Livesey K, Tsang V, McKenna WJ, Jalilzadeh S, Carballo S, Redwood C, Watkins H. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res 2009; 105:219-22; PMID:19574547; http://dx.doi.org/10.1161/CIRCRESAHA.109.202440
   PubMed Web of Science ®Google Scholar
• van Dijk SJ, Dooijes D, dos Remedios C, Michels M, Lamers JM, Winegrad S, Schlossarek S, Carrier L, ten Cate FJ, Stienen GJ, et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 2009; 119:1473-83; PMID:19273718; http://dx.doi.org/10.1161/CIRCULATIONAHA.108.838672
   PubMed Web of Science ®Google Scholar
• Redwood CS, Moolman-Smook JC, Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 1999; 44:20-36; PMID:10615387; http://dx.doi.org/10.1016/S0008-6363(99)00213-8
   PubMed Web of Science ®Google Scholar
• Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001; 104:557-67; PMID:11239412; http://dx.doi.org/10.1016/S0092-8674(01)00242-2
   PubMed Web of Science ®Google Scholar
• Kirschner SE, Becker E, Antognozzi M, Kubis HP, Francino A, Navarro-Lopez F, Bit-Avragim N, Perrot A, Mirrakhimov MM, Osterziel KJ, et al. Hypertrophic cardiomyopathy-related beta-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells. Am J Physiol Heart Circ Physiol 2005; 288:H1242-51; PMID:15550524; http://dx.doi.org/10.1152/ajpheart.00686.2004
   PubMedGoogle Scholar
• Knollmann BC, Kirchhof P, Sirenko SG, Degen H, Greene AE, Schober T, Mackow JC, Fabritz L, Potter JD, Morad M. Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling. Circ Res 2003; 92:428-36; PMID:12600890; http://dx.doi.org/10.1161/01.RES.0000059562.91384.1A
   PubMed Web of Science ®Google Scholar
• Huke S, Knollmann BC. Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility. J Mol Cell Cardiol 2010; 48:824-33; PMID:20097204; http://dx.doi.org/10.1016/j.yjmcc.2010.01.011
   PubMed Web of Science ®Google Scholar
• Bers DM, Guo T. Calcium signaling in cardiac ventricular myocytes. Ann N Y Acad Sci 2005; 1047:86-98; PMID:16093487; http://dx.doi.org/10.1196/annals.1341.008
   PubMed Web of Science ®Google Scholar
• Robinson P, Griffiths PJ, Watkins H, Redwood CS. Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. Circ Res 2007; 101:1266-73; PMID:17932326; http://dx.doi.org/10.1161/CIRCRESAHA.107.156380
   PubMed Web of Science ®Google Scholar
• Kataoka A, Hemmer C, Chase PB. Computational simulation of hypertrophic cardiomyopathy mutations in troponin I: influence of increased myofilament calcium sensitivity on isometric force, ATPase and [Ca2+]i. J Biomech 2007; 40:2044-52; PMID:17140583; http://dx.doi.org/10.1016/j.jbiomech.2006.09.026
   PubMed Web of Science ®Google Scholar
• Smith GA, Dixon HB, Kirschenlohr HL, Grace AA, Metcalfe JC, Vandenberg JI. Ca2+ buffering in the heart: Ca2+ binding to and activation of cardiac myofibrils. Biochem J 2000; 346 Pt 2:393-402; PMID:10677358; http://dx.doi.org/10.1042/bj3460393
   PubMed Web of Science ®Google Scholar
• Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. Trends Genet 2003; 19:263-8; PMID:12711218; http://dx.doi.org/10.1016/S0168-9525(03)00081-7
   PubMed Web of Science ®Google Scholar
• Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, Salmon A, Ostman-Smith I, Watkins H. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001; 10:1215-20; PMID:11371514; http://dx.doi.org/10.1093/hmg/10.11.1215
   PubMed Web of Science ®Google Scholar
• Mercuri E, Brown SC, Nihoyannopoulos P, Poulton J, Kinali M, Richard P, Piercy RJ, Messina S, Sewry C, Burke MM, et al. Extreme variability of skeletal and cardiac muscle involvement in patients with mutations in exon 11 of the lamin A/C gene. Muscle Nerve 2005; 31:602-9; PMID:15770669; http://dx.doi.org/10.1002/mus.20293
   PubMed Web of Science ®Google Scholar
• Nikolova V, Leimena C, McMahon AC, Tan JC, Chandar S, Jogia D, Kesteven SH, Michalicek J, Otway R, Verheyen F, et al. Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. J Clin Invest 2004; 113:357-69; PMID:14755333; http://dx.doi.org/10.1172/JCI200419448
   PubMed Web of Science ®Google Scholar
• Sen-Chowdhry S, McKenna WJ. The utility of magnetic resonance imaging in the evaluation of arrhythmogenic right ventricular cardiomyopathy. Curr Opin Cardiol 2008; 23:38-45; PMID:18281826; http://dx.doi.org/10.1097/HCO.0b013e3282f2c96e
   PubMed Web of Science ®Google Scholar
• Sen-Chowdhry S, Morgan RD, Chambers JC, McKenna WJ. Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Ann Rev Med 2010; 61:233-53; PMID:20059337; http://dx.doi.org/10.1146/annurev.med.052208.130419
   PubMed Web of Science ®Google Scholar
• McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, Fontaine G, Camerini F. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 1994; 71:215-8; PMID:8142187; http://dx.doi.org/10.1136/hrt.71.3.215
   PubMedGoogle Scholar
• Tabib A, Loire R, Chalabreysse L, Meyronnet D, Miras A, Malicier D, Thivolet F, Chevalier P, Bouvagnet P. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation 2003; 108:3000-5; PMID:14662701; http://dx.doi.org/10.1161/01.CIR.0000108396.65446.21
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Fabritz L, Zwiener M, Witt H, Schafers M, Zellerhoff S, Paul M, Athai T, Hiller KH, Baba HA, et al. Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation 2006; 114:1799-806; PMID:17030684; http://dx.doi.org/10.1161/CIRCULATIONAHA.106.624502
   PubMed Web of Science ®Google Scholar
• Asimaki A, Syrris P, Wichter T, Matthias P, Saffitz JE, McKenna WJ. A novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2007; 81:964-73; PMID:17924338; http://dx.doi.org/10.1086/521633
   PubMed Web of Science ®Google Scholar
• Protonotarios N, Tsatsopoulou A. Naxos disease and Carvajal syndrome: cardiocutaneous disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Pathol 2004; 13:185-94; PMID:15210133; http://dx.doi.org/10.1016/j.carpath.2004.03.609
   PubMed Web of Science ®Google Scholar
• Sen-Chowdhry S, Syrris P, McKenna WJ. Genetics of right ventricular cardiomyopathy. J Cardiovasc Electrophysiol 2005; 16:927-35; PMID:16101641; http://dx.doi.org/10.1111/j.1540-8167.2005.40842.x
   PubMed Web of Science ®Google Scholar
• Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2007; 50:1813-21; PMID:17980246; http://dx.doi.org/10.1016/j.jacc.2007.08.008
   PubMed Web of Science ®Google Scholar
• Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, Khoury DS, Marian AJ. Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest 2006; 116:2012-21; PMID:16823493; http://dx.doi.org/10.1172/JCI27751
   PubMed Web of Science ®Google Scholar
• MacRae CA, Birchmeier W, Thierfelder L. Arrhythmogenic right ventricular cardiomyopathy: moving toward mechanism. J Clin Invest 2006; 116:1825-8; PMID:16823481; http://dx.doi.org/10.1172/JCI29174
   PubMed Web of Science ®Google Scholar
• Larsen MK, Nissen PH, Berge KE, Leren TP, Kristensen IB, Jensen HK, Banner J. Molecular autopsy in young sudden cardiac death victims with suspected cardiomyopathy. Forensic Sci Int 2012; 219:33-8; PMID:22177269; http://dx.doi.org/10.1016/j.forsciint.2011.11.020
   PubMed Web of Science ®Google Scholar
• Quarta G, Syrris P, Ashworth M, Jenkins S, Zuborne Alapi K, Morgan J, Muir A, Pantazis A, McKenna WJ, Elliott PM. Mutations in the Lamin A/C gene mimic arrhythmogenic right ventricular cardiomyopathy. Euro Heart J 2011; 33(9):1128-36; PMID:22199124
   PubMed Web of Science ®Google Scholar
• Markiewicz E, Tilgner K, Barker N, van de Wetering M, Clevers H, Dorobek M, Hausmanowa-Petrusewicz I, Ramaekers FC, Broers JL, Blankesteijn WM, et al. The inner nuclear membrane protein emerin regulates beta-catenin activity by restricting its accumulation in the nucleus. EMBO J 2006; 25:3275-85; PMID:16858403; http://dx.doi.org/10.1038/sj.emboj.7601230
   PubMed Web of Science ®Google Scholar
• Arimura T, Helbling-Leclerc A, Massart C, Varnous S, Niel F, Lacene E, Fromes Y, Toussaint M, Mura AM, Keller DI, et al. Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum Mol Genet 2005; 14:155-69; PMID:15548545; http://dx.doi.org/10.1093/hmg/ddi017
   PubMed Web of Science ®Google Scholar
• Muchir A, Pavlidis P, Decostre V, Herron AJ, Arimura T, Bonne G, Worman HJ. Activation of MAPK pathways links LMNA mutations to cardiomyopathy in Emery-Dreifuss muscular dystrophy. J Clin Invest 2007; 117:1282-93; PMID:17446932; http://dx.doi.org/10.1172/JCI29042
   PubMed Web of Science ®Google Scholar
• Muchir A, Shan J, Bonne G, Lehnart SE, Worman HJ. Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins. Hum Mol Genet 2009; 18:241-7; PMID:18927124; http://dx.doi.org/10.1093/hmg/ddn343
   PubMed Web of Science ®Google Scholar
• Wu W, Shan J, Bonne G, Worman HJ, Muchir A. Pharmacological inhibition of c-Jun N-terminal kinase signaling prevents cardiomyopathy caused by mutation in LMNA gene. Biochim Biophys Acta 2010; 1802:632-8; PMID:20388542; http://dx.doi.org/10.1016/j.bbadis.2010.04.001
   PubMed Web of Science ®Google Scholar
• Wu W, Muchir A, Shan J, Bonne G, Worman HJ. Mitogen-Activated Protein Kinase Inhibitors Improve Heart Function and Prevent Fibrosis in Cardiomyopathy Caused by Mutation in Lamin A/C Gene. Circulation 2010; 123:53-61; PMID:21173351; http://dx.doi.org/10.1161/CIRCULATIONAHA.110.970673
   PubMed Web of Science ®Google Scholar
• Muchir A, Reilly Sa, Wu W, Iwata S, Homma S, Bonne G, Worman HJ. Treatment with selumetinib preserves cardiac function and improves survival in cardiomyopathy caused by mutation in the lamin A/C gene. Cardiovasc Res 2012; 93:311-9; PMID:22068161; http://dx.doi.org/10.1093/cvr/cvr301
   PubMed Web of Science ®Google Scholar
• Choi JC, Wu W, Muchir A, Iwata S, Homma S, Worman HJ. Dual specificity phosphatase 4 mediates cardiomyopathy caused by lamin A/C (LMNA) gene mutation. J Biol Chem 2012:1-24
   Web of Science ®Google Scholar
• Choi JC, Muchir A, Wu W, Iwata S, Homma S, Morrow JP, Worman HJ. Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation. Sci Transl Med 2012; 4:144ra02; ; http://dx.doi.org/10.1126/scitranslmed.3003875
   Web of Science ®Google Scholar
• Muchir A, Wu W, Sera F, Homma S, Worman HJ. Mitogen-activated protein kinase kinase 1/2 inhibition and angiotensin II converting inhibition in mice with cardiomyopathy caused by lamin A/C gene mutation. Biochem Biophys Res Commun 2014; 452:958-61; PMID:25218145; http://dx.doi.org/10.1016/j.bbrc.2014.09.020
   PubMed Web of Science ®Google Scholar
• Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, Atherton J, Vidaillet HJ, Jr., Spudich S, De Girolami U, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999; 341:1715-24; PMID:10580070; http://dx.doi.org/10.1056/NEJM199912023412302
   PubMed Web of Science ®Google Scholar
• Mounkes LC, Kozlov SV, Rottman JN, Stewart CL. Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. Hum Mol Genet 2005; 14:2167-80; PMID:15972724; http://dx.doi.org/10.1093/hmg/ddi221
   PubMed Web of Science ®Google Scholar
• Nguyen-Tran VT, Kubalak SW, Minamisawa S, Fiset C, Wollert KC, Brown AB, Ruiz-Lozano P, Barrere-Lemaire S, Kondo R, Norman LW, et al. A novel genetic pathway for sudden cardiac death via defects in the transition between ventricular and conduction system cell lineages. Cell 2000; 102:671-82; PMID:11007485; http://dx.doi.org/10.1016/S0092-8674(00)00089-1
   PubMed Web of Science ®Google Scholar
• Cattin M-E, Bertrand AT, Schlossarek S, Le Bihan MC, Skov Jensen S, Neuber C, Crocini C, Maron S, Lainé J, Mougenot N, et al. Heterozygous LmnadelK32 mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicity. Hum Mol Genet 2013; 22(15):3152-64
   PubMed Web of Science ®Google Scholar
• Quijano-Roy S, Mbieleu B, Bonnemann CG, Jeannet PY, Colomer J, Clarke NF, Cuisset JM, Roper H, De Meirleir L, D'Amico A, et al. De novo LMNA mutations cause a new form of congenital muscular dystrophy. Ann Neurol 2008; 64:177-86; PMID:18551513; http://dx.doi.org/10.1002/ana.21417
   PubMed Web of Science ®Google Scholar
• Cattin ME, Ferry A, Vignaud A, Mougenot N, Jacquet A, Wahbi K, Bertrand AT, Bonne G. Mutation in lamin A/C sensitizes the myocardium to exercise-induced mechanical stress but has no effect on skeletal muscles in mouse. Neuromuscul Disord 2016; 26(8):490-9; PMID:27287550
   PubMed Web of Science ®Google Scholar
• Bonne G, Mercuri E, Muchir A, Urtizberea A, Becane HM, Recan D, Merlini L, Wehnert M, Boor R, Reuner U, et al. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Ann Neurol 2000; 48:170-80; PMID:10939567; http://dx.doi.org/10.1002/1531-8249(200008)48:2%3c170::AID-ANA6%3e3.0.CO;2-J
   PubMed Web of Science ®Google Scholar
• Wang Y, Herron AJ, Worman HJ. Pathology and nuclear abnormalities in hearts of transgenic mice expressing M371K lamin A encoded by an LMNA mutation causing Emery-Dreifuss muscular dystrophy. Hum Mol Genet 2006; 15:2479-89; PMID:16825283; http://dx.doi.org/10.1093/hmg/ddl170
   PubMed Web of Science ®Google Scholar
• Lu D, Lian H, Zhang X, Shao H, Huang L, Qin C, Zhang L. LMNA E82K mutation activates FAS and mitochondrial pathways of apoptosis in heart tissue specific transgenic mice. PLoS One 2010; 5:e15167; PMID:21151901; http://dx.doi.org/10.1371/journal.pone.0015167
   PubMedGoogle Scholar
• Mounkes LC, Kozlov S, Hernandez L, Sullivan T, Stewart CL. A progeroid syndrome in mice is caused by defects in A-type lamins. Nature 2003; 423:298-301; PMID:12748643; http://dx.doi.org/10.1038/nature01631
   PubMed Web of Science ®Google Scholar
• Zuela N, Zwerger M, Levin T, Medalia O, Gruenbaum Y. Impaired mechanical response of an EDMD mutation leads to motility phenotypes that are repaired by loss of prenylation. J Cell Sci 2016; 129:1781-91; PMID:27034135; http://dx.doi.org/10.1242/jcs.184309
   PubMed Web of Science ®Google Scholar
• Ramos FJ, Chen SC, Garelick MG, Dai DF, Liao CY, Schreiber KH, MacKay VL, An EH, Strong R, Ladiges WC, et al. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Medi 2012; 4:144ra03; http://dx.doi.org/10.1126/scitranslmed.3003802
   Web of Science ®Google Scholar
• Nikolova-Krstevski V, Leimena C, Xiao X-H, Kesteven S, Tan JC, Yeo LS, Yu Z-Y, Zhang Q, Carlton A, Head S, et al. Nesprin-1 and actin contribute to nuclear and cytoskeletal defects in lamin A/C-deficient cardiomyopathy. J Mol Cell Cardiol 2011; 50:479-86; PMID:21156181; http://dx.doi.org/10.1016/j.yjmcc.2010.12.001
   PubMed Web of Science ®Google Scholar
• Chen SC, Kennedy BK, Lampe PD. Phosphorylation of connexin43 on S279/282 may contribute to laminopathy-associated conduction defects. Exp Cell Res 2013; 319:888-96; PMID:23261543; http://dx.doi.org/10.1016/j.yexcr.2012.12.014
   PubMed Web of Science ®Google Scholar
• Frock RL, Chen SC, Da D-F, Frett E, Lau C, Brown C, Pak DN, Wang Y, Muchir A, Worman HJ, et al. Cardiomyocyte-specific expression of lamin a improves cardiac function in lmna(−/−) mice. PloS One 2012; 7:e42918; PMID:22905185; http://dx.doi.org/10.1371/journal.pone.0042918
   PubMed Web of Science ®Google Scholar
• Wolf CM, Wang L, Alcalai R, Pizard A, Burgon PG, Ahmad F, Sherwood M, Branco DM, Wakimoto H, Fishman GI, et al. Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. J Mol Cell Cardiol 2008; 44:293-303; PMID:18182166; http://dx.doi.org/10.1016/j.yjmcc.2007.11.008
   PubMed Web of Science ®Google Scholar
• Chandar S, Yeo LS, Leimena C, Tan J-C, Xiao X-H, Nikolova-Krstevski V, Yasuoka Y, Gardiner-Garden M, Wu J, Kesteven S, et al. Effects of mechanical stress and carvedilol in lamin A/C-deficient dilated cardiomyopathy. Circulat Res 2010; 106:573-82; PMID:20019332; http://dx.doi.org/10.1161/CIRCRESAHA.109.204388
   PubMed Web of Science ®Google Scholar
• Cupesi M, Yoshioka J, Gannon J, Kudinova A, Stewart CL, Lammerding J. Attenuated hypertrophic response to pressure overload in a lamin A/C haploinsufficiency mouse. J Mol Cell Cardiol 2010; 48:1290-7; PMID:19913544; http://dx.doi.org/10.1016/j.yjmcc.2009.10.024
   PubMed Web of Science ®Google Scholar
• Zwerger M, Jaalouk DE, Lombardi ML, Isermann P, Mauermann M, Dialynas G, Herrmann H, Wallrath LL, Lammerding J. Myopathic lamin mutations impair nuclear stability in cells and tissue and disrupt nucleo-cytoskeletal coupling. Hum Mol Genet 2013; 22:2335-49; PMID:23427149; http://dx.doi.org/10.1093/hmg/ddt079
   PubMed Web of Science ®Google Scholar
• Bhattacharjee P, Banerjee A, Banerjee A, Dasgupta D, Sengupta K. Structural alterations of Lamin A protein in dilated cardiomyopathy. Biochemistry 2013; 52:4229-41; PMID:23701190; http://dx.doi.org/10.1021/bi400337t
   PubMed Web of Science ®Google Scholar
• West G, Gullmets J, Virtanen L, Li SP, Keinanen A, Shimi T, Mauermann M, Helio T, Kaartinen M, Ollila L, et al. Deleterious assembly of mutant p.S143P lamin A/C causes ER stress in familial dilated cardiomyopathy. J Cell Sci 2016; 129(14):2732-43; PMID:27235420
   PubMed Web of Science ®Google Scholar
• Banerjee A, Rathee V, Krishnaswamy R, Bhattacharjee P, Ray P, Sood AK, Sengupta K. Viscoelastic behavior of human lamin A proteins in the context of dilated cardiomyopathy. PLoS One 2013; 8:e83410; PMID:24386194; http://dx.doi.org/10.1371/journal.pone.0083410
   PubMed Web of Science ®Google Scholar
• Lammerding J, Fong LG, Ji JY, Reue K, Stewart CL, Young SG, Lee RT. Lamins A and C but not lamin B1 regulate nuclear mechanics. J Biol Chem 2006; 281:25768-80; PMID:16825190; http://dx.doi.org/10.1074/jbc.M513511200
   PubMed Web of Science ®Google Scholar
• Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, Kamm RD, Stewart CL, Lee RT. Lamin A / C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest 2004; 113:370-8
   PubMed Web of Science ®Google Scholar
• Lammerding J, Hsiao J, Schulze PC, Kozlov S, Stewart CL, Lee RT. Abnormal nuclear shape and impaired mechanotransduction in emerin-deficient cells. J Cell Biol 2005; 170:781-91; PMID:16115958; http://dx.doi.org/10.1083/jcb.200502148
   PubMed Web of Science ®Google Scholar
• Lammerding J, Lee RT. The nuclear membrane and mechanotransduction: impaired nuclear mechanics and mechanotransduction in lamin A/C deficient cells. Novartis Found Symp 2005; 264:264-73; discussion 73–8; PMID:15773759; http://dx.doi.org/10.1002/0470093765.ch18
   PubMedGoogle Scholar
• Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, Kamm RD, Stewart CL, Lee RT. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest 2004; 113:370-8; PMID:14755334; http://dx.doi.org/10.1172/JCI200419670
   PubMed Web of Science ®Google Scholar
• Siu CW, Lee YK, Ho JC, Lai WH, Chan YC, Ng KM, Wong LY, Au KW, Lau YM, Zhang J, et al. Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells. Aging (Albany NY) 2012; 4:803-22; PMID:23362510; http://dx.doi.org/10.18632/aging.100503
   PubMedGoogle Scholar
• De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003; 300:2055; PMID:12702809; http://dx.doi.org/10.1126/science.1084125
   PubMed Web of Science ®Google Scholar
• De Sandre-Giovannoli A, Levy N. Altered splicing in prelamin A-associated premature aging phenotypes. Prog Mol Subcell Biol 2006; 44:199-232; PMID:17076270; http://dx.doi.org/10.1007/978-3-540-34449-0_9
   PubMedGoogle Scholar
• De Sandre-giovannoli AD, Cau P, Navarro C, Amiel J, Lyonnet S, Stewart CL, Munnich A, Merrer ML, Le N. Lamin A Truncation in Hutichnson-Gilford Progeria. Science 2003; 300:21702; http://dx.doi.org/10.1126/science.1084125
   Web of Science ®Google Scholar
• Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003; 423:293-8; PMID:12714972; http://dx.doi.org/10.1038/nature01629
   PubMed Web of Science ®Google Scholar
• Shackleton S, Smallwood DT, Clayton P, Wilson LC, Agarwal aK, Garg a, Trembath RC. Compound heterozygous ZMPSTE24 mutations reduce prelamin A processing and result in a severe progeroid phenotype. J Med Genet 2005; 42:e36; PMID:15937076; http://dx.doi.org/10.1136/jmg.2004.029751
   PubMed Web of Science ®Google Scholar
• Ragnauth CD, Warren DT, Liu Y, McNair R, Tajsic T, Figg N, Shroff R, Skepper J, Shanahan CM. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010; 121:2200-10; PMID:20458013; http://dx.doi.org/10.1161/CIRCULATIONAHA.109.902056
   PubMed Web of Science ®Google Scholar
• Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, Gruenbaum Y, Khuon S, Mendez M, Varga R, et al. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2004; 101:8963-8; PMID:15184648; http://dx.doi.org/10.1073/pnas.0402943101
   PubMed Web of Science ®Google Scholar
• Liu Y, Rusinol A, Sinensky M, Wang Y, Zou Y. DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A. J Cell Sci 2006; 119:4644-9; PMID:17062639; http://dx.doi.org/10.1242/jcs.03263
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Y, Rusinol AE, Sinensky MS, Liu J, Shell SM, Zou Y. Involvement of xeroderma pigmentosum group A (XPA) in progeria arising from defective maturation of prelamin A. FASEB J 2008; 22:603-11; PMID:17848622; http://dx.doi.org/10.1096/fj.07-8598com
   PubMed Web of Science ®Google Scholar
• Liu B, Wang J, Chan KM, Tjia WM, Deng W, Guan X, Huang JD, Li KM, Chau PY, Chen DJ, et al. Genomic instability in laminopathy-based premature aging. Nat Med 2005; 11:780-5; PMID:15980864; http://dx.doi.org/10.1038/nm1266
   PubMed Web of Science ®Google Scholar
• Misteli T, Scaffidi P. Genome instability in progeria: when repair gets old. Nat Med 2005; 11:718-9; PMID:16015360; http://dx.doi.org/10.1038/nm0705-718
   PubMed Web of Science ®Google Scholar
• Cobb AM, Larrieu D, Warren DT, Liu Y, Srivastava S, Smith AJ, Bowater RP, Jackson SP, Shanahan CM. Prelamin A impairs 53BP1 nuclear entry by mislocalizing NUP153 and disrupting the Ran gradient. Aging cell 2016; 15:1039–1050. PMID:27464478
   PubMedGoogle Scholar
• Olive M, Harten I, Mitchell R, Beers JK, Djabali K, Cao K, Erdos MR, Blair C, Funke B, Smoot L, et al. Cardiovascular Pathology in Hutchinson-Gilford Progeria: Correlation With the Vascular Pathology of Aging. Arterioscler Thromb Vasc Biol 2010; 30:2301-9; PMID:20798379; http://dx.doi.org/10.1161/ATVBAHA.110.209460
   PubMed Web of Science ®Google Scholar
• Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Kleinman ME, Miller DT, Schwartzman A, Giobbie-Hurder A, Neuberg D, Gordon LB. Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. Hypertension 2012; 59:92-7; PMID:22083160; http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.180919
   PubMed Web of Science ®Google Scholar
• Osorio FG, Navarro CL, Cadinanos J, Lopez-Mejia IC, Quiros PM, Bartoli C, Rivera J, Tazi J, Guzman G, Varela I, et al. Splicing-Directed Therapy in a New Mouse Model of Human Accelerated Aging. Sci Transl Med 2011; 3:106ra7-ra7; http://dx.doi.org/10.1126/scitranslmed.3002847
   Web of Science ®Google Scholar
• Pendás AM, Zhou Z, Cadiñanos J, Freije JMP, Wang J, Hultenby K, Astudillo A, Wernerson A, Rodríguez F, Tryggvason K, et al. Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet 2002; 31:94-9
   PubMed Web of Science ®Google Scholar
• Davies BSJ, Barnes RH, Tu Y, Ren S, Andres DA, Spielmann HP, Lammerding J, Wang Y, Young SG, Fong LG, et al. An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet 2010; 19:2682-94; PMID:20421363; http://dx.doi.org/10.1093/hmg/ddq158
   PubMed Web of Science ®Google Scholar
• Brodsky GL, Bowersox JA, Fitzgerald-miller L, Miller LA, Maclean KN. The prelamin A pre-peptide induces cardiac and skeletal myoblast differentiation. Biochem Biophys Res Commun 2007; 356:872-9; PMID:17389141; http://dx.doi.org/10.1016/j.bbrc.2007.03.062
   PubMed Web of Science ®Google Scholar
• Cattin ME, Muchir A, Bonne G. 'State-of-the-heart' of cardiac laminopathies. Curr Opin Cardiol 2013; 28:297-304; PMID:23455585; http://dx.doi.org/10.1097/HCO.0b013e32835f0c79
   PubMed Web of Science ®Google Scholar
• Lu JT, Muchir A, Nagy PL, Worman HJ. LMNA cardiomyopathy: cell biology and genetics meet clinical medicine. Dis Models Mech 2011; 4:562-8; PMID:21810905; http://dx.doi.org/10.1242/dmm.006346
   PubMed Web of Science ®Google Scholar
• Scharner J, Figeac N, Ellis JA, Zammit PS. Ameliorating pathogenesis by removing an exon containing a missense mutation: a potential exon-skipping therapy for laminopathies. Gene Ther 2015; 22:503-15; PMID:25832542; http://dx.doi.org/10.1038/gt.2015.8
   PubMed Web of Science ®Google Scholar
• Lee JM, Nobumori C, Tu Y, Choi C, Yang SH, Jung HJ, Vickers TA, Rigo F, Bennett CF, Young SG, et al. Modulation of LMNA splicing as a strategy to treat prelamin A diseases. J Clin Invest 2016; 126:1592-602; PMID:26999604; http://dx.doi.org/10.1172/JCI85908
   PubMed Web of Science ®Google Scholar
• Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland R, Snyder BD, et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2012; 109:16666-71; PMID:23012407; http://dx.doi.org/10.1073/pnas.1202529109
   PubMed Web of Science ®Google Scholar
• Gordon LB, Kleinman ME, Massaro J, D'Agostino RB, Sr, Shappell H, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland RH, Nazarian A, et al. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation 2016; 134:114-25; PMID:27400896; http://dx.doi.org/10.1161/CIRCULATIONAHA.116.022188
   PubMed Web of Science ®Google Scholar
• Ibrahim MX, Sayin VI, Akula MK, Liu M, Fong LG, Young SG, Bergo MO. Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria. Science 2013; 340:1330-3; PMID:23686339; http://dx.doi.org/10.1126/science.1238880
   PubMed Web of Science ®Google Scholar
• Larrieu D, Britton S, Demir M, Rodriguez R, Jackson SP. Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science 2014; 344:527-32; PMID:24786082; http://dx.doi.org/10.1126/science.1252651
   PubMed Web of Science ®Google Scholar
• Rankin J, Auer-Grumbach M, Bagg W, Colclough K, Nguyen TD, Fenton-May J, Hattersley A, Hudson J, Jardine P, Josifova D, et al. Extreme phenotypic diversity and nonpenetrance in families with the LMNA gene mutation R644C. Am J Med Genet Part A 2008; 146A:1530-42; PMID:18478590; http://dx.doi.org/10.1002/ajmg.a.32331
   PubMed Web of Science ®Google Scholar